Compare · BCDA vs BNTX
BCDA vs BNTX
Side-by-side comparison of BioCardia Inc. (BCDA) and BioNTech SE (BNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCDA and BNTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.99B, about 2447.6x BCDA ($9.4M).
- Over the past year, BCDA is down 65.0% and BNTX is down 16.0% - BNTX leads by 49.0 points.
- BCDA has hit the wire 15 times in the past 4 weeks while BNTX has been quiet.
- BNTX has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- BioCardia Inc.
- BioNTech SE
- Price
- $0.82-5.77%
- $91.56-0.03%
- Market cap
- $9.4M
- $22.99B
- 1M return
- -4.78%
- +2.30%
- 1Y return
- -64.95%
- -15.96%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 15
- 0
- Recent ratings
- 1
- 25
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BCDA
- President and CEO Altman Peter bought $3,754 worth of shares (4,300 units at $0.87), increasing direct ownership by 1% to 368,385 units (SEC Form 4)
- President and CEO Altman Peter bought $7,175 worth of shares (7,500 units at $0.96), increasing direct ownership by 2% to 369,485 units (SEC Form 4)
- President and CEO Altman Peter bought $5,208 worth of shares (5,400 units at $0.96), increasing direct ownership by 2% to 361,985 units (SEC Form 4)
- SEC Form 4 filed by Director Stertzer Simon H
- SEC Form 4 filed by Director Slosman Marvin
- President and CEO Altman Peter covered exercise/tax liability with 54,606 shares, decreasing direct ownership by 13% to 356,585 units (SEC Form 4)
- Chief Financial Officer Mcclung David covered exercise/tax liability with 23,125 shares, decreasing direct ownership by 17% to 114,245 units (SEC Form 4)
- Senior Vice President, Devices Gillis Edward M covered exercise/tax liability with 17,269 shares, decreasing direct ownership by 24% to 54,126 units (SEC Form 4)
- SEC Form 4 filed by Director Blank Andrew Scott
- SEC Form 4 filed by Director Allen Jim L.
Latest BNTX
- SEC Form 3 filed by new insider Low-Friedrich Iris Katharina
- SEC Form 3 filed by new insider Schaffert Susanne
- The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE